Macquarie Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$59.3M Sell
273,227
-712,817
-72% -$158M 0.35% 59
2025
Q4
$225M Buy
986,044
+51,559
+6% +$11.7M 0.98% 14
2025
Q3
$216M Buy
934,485
+337,911
+57% +$68.8M 0.25% 61
2025
Q2
$111M Sell
596,574
-210,412
-26% -$39.1M 0.14% 204
2025
Q1
$169M Buy
806,986
+84,265
+12% +$16.4M 0.21% 107
2024
Q4
$116M Buy
722,721
+196,709
+37% +$36.2M 0.14% 204
2024
Q3
$104M Buy
526,012
+25,858
+5% +$4.83M 0.11% 251
2024
Q2
$85.8M Buy
500,154
+56,229
+13% +$9.31M 0.1% 267
2024
Q1
$80.8M Sell
443,925
-71,668
-14% -$12.4M 0.09% 282
2023
Q4
$79.9M Sell
515,593
-248,602
-33% -$36.2M 0.09% 300
2023
Q3
$74.4M Buy
764,195
+323,367
+73% +$47.5M 0.09% 292
2023
Q2
$59.4M Sell
440,828
-67,809
-13% -$9.94M 0.07% 377
2023
Q1
$81.1M Buy
508,637
+52,064
+11% +$7.96M 0.1% 282
2022
Q4
$73.8M Buy
456,573
+18,881
+4% +$2.9M 0.09% 323
2022
Q3
$58.7M Sell
437,692
-31,065
-7% -$4.46M 0.07% 374
2022
Q2
$71.8M Sell
468,757
-104,976
-18% -$16M 0.08% 339
2022
Q1
$93K Sell
573,733
-161,885
-22% -$23.5M 0.07% 314
2021
Q4
$99.6M Sell
735,618
-23,294
-3% -$2.75M 0.08% 305
2021
Q3
$81.9M Sell
758,912
-135,931
-15% -$15.5M 0.07% 363
2021
Q2
$101M Sell
894,843
-74,827
-8% -$8.43M 0.08% 302
2021
Q1
$105M Buy
969,670
+297,561
+44% +$31.8M 0.15% 147
2020
Q4
$72M Buy
672,109
+124,760
+23% +$12M 0.11% 218
2020
Q3
$47.9M Buy
547,349
+112,365
+26% +$10.6M 0.08% 277
2020
Q2
$42.7M Buy
434,984
+140,866
+48% +$12.4M 0.07% 286
2020
Q1
$22.4M Buy
294,118
+126,981
+76% +$10.8M 0.05% 387
2019
Q4
$14.8M Sell
167,137
-2,798
-2% -$232K 0.02% 579
2019
Q3
$12.9M Sell
169,935
-73,287
-30% -$5.02M 0.02% 545
2019
Q2
$17.7M Sell
243,222
-11,680
-5% -$918K 0.03% 484
2019
Q1
$20.5M Sell
254,902
-3,780
-1% -$309K 0.04% 457
2018
Q4
$23.8M Sell
258,682
-154,986
-37% -$13.6M 0.05% 384
2018
Q3
$39.1M Sell
413,668
-28,620
-6% -$2.71M 0.06% 319
2018
Q2
$41M Buy
442,288
+12,938
+3% +$1.26M 0.07% 307
2018
Q1
$40.6M Sell
429,350
-51,316
-11% -$5.64M 0.07% 280
2017
Q4
$46.6M Buy
480,666
+143,538
+43% +$13.5M 0.08% 233
2017
Q3
$30M Sell
337,128
-31,691
-9% -$2.41M 0.05% 359
2017
Q2
$26.7M Buy
368,819
+28,384
+8% +$1.91M 0.05% 377
2017
Q1
$22.2M Sell
340,435
-123,470
-27% -$7.76M 0.04% 432
2016
Q4
$29M Sell
463,905
-361,030
-44% -$22M 0.06% 321
2016
Q3
$52M Sell
824,935
-601,359
-42% -$38.9M 0.1% 168
2016
Q2
$88.3M Buy
1,426,294
+687,029
+93% +$41.9M 0.09% 192
2016
Q1
$42.2M Sell
739,265
-1,570
-0.2% -$87.5K 0.09% 201
2015
Q4
$43.9M Buy
740,835
+138,539
+23% +$7.98M 0.09% 203
2015
Q3
$32.8M Buy
602,296
+49,006
+9% +$3.19M 0.07% 252
2015
Q2
$37.2M Sell
553,290
-162,550
-23% -$10.6M 0.07% 249
2015
Q1
$41.9M Sell
715,840
-75,864
-10% -$4.58M 0.08% 239
2014
Q4
$51.8M Sell
791,704
-38,749
-5% -$2.44M 0.11% 186
2014
Q3
$48M Sell
830,453
-13,128
-2% -$729K 0.1% 182
2014
Q2
$47.6M Sell
843,581
-69,645
-8% -$3.65M 0.11% 185
2014
Q1
$46.9M Buy
913,226
+117,470
+15% +$5.94M 0.08% 182
2013
Q4
$42M Buy
795,756
+95,029
+14% +$4.67M 0.08% 194
2013
Q3
$31.3M Buy
700,727
+11,792
+2% +$523K 0.06% 241
2013
Q2
$28.5M Buy
+688,935
New +$30.1M 0.06% 243

Other funds holding ABBV

Macquarie Group's ABBV Position: Q1 2026 in Review

Macquarie Group reduced its AbbVie (ABBV) stake by 72% in Q1 2026, selling an estimated $158M and leaving 273,227 shares worth $59.3M. The position accounts for 0.35% of the portfolio, ranked #59.

Macquarie Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $225M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Macquarie Group held 273,227 shares of AbbVie worth $59.3M as of Q1 2026.
  • Macquarie Group sold 712,817 AbbVie shares in Q1 2026, an estimated $158M.
  • AbbVie made up 0.35% of Macquarie Group's portfolio in Q1 2026, its #59 holding.
  • Macquarie Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Macquarie Group's AbbVie position peaked at $225M in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Macquarie Group's 13F filing for Q1 2026, filed 15 May 2026.